Trade Representative, Office of United States September 2015 – Federal Register Recent Federal Regulation Documents

Children's Online Privacy Protection Rule Proposed Parental Consent Method; Jest8 Limited Trading as Riyo's Application for Approval of Parental Consent Method; Extension of Comment Period
Document Number: 2015-21979
Type: Proposed Rule
Date: 2015-09-04
Agency: Trade Representative, Office of United States
The Federal Trade Commission is extending the comment period concerning the proposed parental consent method submitted by Jest8 Limited, trading as Riyo (``Riyo''), under the Voluntary Commission Approval Processes provision of the Children's Online Privacy Protection Rule.
Ophthalmic Practice Rules (Eyeglass Rule)
Document Number: 2015-21578
Type: Proposed Rule
Date: 2015-09-03
Agency: Trade Representative, Office of United States
The Commission is requesting public comment on its Trade Regulation Rule entitled ``Ophthalmic Practice Rules (Eyeglass Rule),'' which requires eye care practitioners to release eyeglass prescriptions to their patients (``Eyeglass Rule''). The Commission is soliciting comments about the efficiency, costs, benefits, and regulatory impact of the Rule as part of its systematic review of all current Commission regulations and guides. All interested persons are hereby given notice of the opportunity to submit written data, views, and arguments concerning the Rule.
Contact Lens Rule
Document Number: 2015-21577
Type: Proposed Rule
Date: 2015-09-03
Agency: Trade Representative, Office of United States
The Commission is requesting public comments on the Contact Lens Rule, which requires that eyecare prescribers provide a copy of a consumer's prescription to the consumer upon completion of a contact lens fitting and verify or provide prescriptions to authorized third parties. The Rule also mandates that a contact lens seller may sell contact lenses only in accordance with a prescription that the seller either: (a) Has received from the patient or prescriber; or (b) has verified through direct communication with the prescriber. The Commission is soliciting comments about the efficiency, costs, benefits, and regulatory impact of the Rule as part of its systematic review of all current Commission regulations and guides. All interested persons are hereby given notice of the opportunity to submit written data, views, and arguments concerning the Rule.